Matthew Richard Moore Arcutis Biotherapeutics, Inc. (ARQT) insider trading activity

Matthew Richard Moore is SVP and Chief Business Officer of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 145,505 shares of ARQT, which is worth approximately $1.35 Million. The most recent transaction as insider was on May 02, 2024, when has been sold 4,681 shares (Common Stock) at a price of $8.74 per share, resulting in proceeds of $40,911. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 146K

0.35% 3M change

1144.7% 12M change

Total Value Held $1.35 Million

Matthew Richard Moore Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 02 2024	SELL Open market or private sale	$40,911 $8.74 p/Share	4,681 Reduced 3.12%	145,505 Common Stock
May 01 2024	BUY Grant, award, or other acquisition	-	4,166 Added 2.7%	150,186 Common Stock
Mar 04 2024	SELL Open market or private sale	$38,564 $11.12 p/Share	3,468 Reduced 2.32%	146,020 Common Stock
Feb 13 2024	BUY Grant, award, or other acquisition	-	94,898 Added 38.83%	149,488 Common Stock
Jan 12 2024	BUY Grant, award, or other acquisition	-	28,000 Added 33.9%	54,590 Common Stock
Mar 02 2023	SELL Open market or private sale	$26,033 $16.17 p/Share	1,610 Reduced 12.11%	11,690 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	14,900 Added 35.91%	26,590 Common Stock

Mar 03 2022	BUY Grant, award, or other acquisition	-	13,300 Added 50.0%	13,300 Common Stock

Also insider at

VTYX

Ventyx Biosciences, Inc. Healthcare

Chief Operating Officer

MRM